Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | VDR | P11473 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948398 | 0.86 | STAT3 (0.60) | AURKANR1I2CYP1A2VDRCYP2C9 | |
| SCHEMBL17687652 | 0.85 | STAT3 (0.57) | AURKANR1I2CYP1A2VDRCYP2C9 | |
| SCHEMBL2948397 | 0.84 | AURKA (0.44) | AURKANR1I2CYP1A2VDRCYP2C9 | |
| SCHEMBL585528 | 0.83 | STAT3 (0.62) | AURKANR1I2CYP1A2VDRCYP2C9 | |
| SCHEMBL31055740 | 0.83 | STAT3 (0.62) | AURKANR1I2CYP1A2VDRCYP2C9 | |
| SCHEMBL226837 | 0.79 | STAT3 (0.59) | CYP1A2CYP2C9MAPK13RAF1MAPK12 | |
| Anisole SCHEMBL28270507 | 0.79 | CA4 (0.48) | NR1I2CYP1A2VDRCYP2C9CYP2B6 | |
| SCHEMBL1945085 | 0.78 | STAT3 (0.49) | AURKAMAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL6265476 | 0.78 | STAT3 (0.57) | CYP1A2CYP2C9MAPK13RAF1MAPK12 | |
| SCHEMBL14054511 | 0.78 | STAT3 (0.57) | CYP1A2CYP2C9MAPK13RAF1MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3206987-B2 | NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | UNIV CHICAGO (US) | 2024-07-24 | — | — | EP | disclosed |
| US-10806694-B2 | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | THE UNIVERSITY OF CHICAGO (US) | 2020-10-20 | — | — | US | disclosed |
| US-10780045-B2 | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof | THE UNIVERSITY OF CHICAGO (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3206987-B1 | NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | UNIV CHICAGO (US) | 2020-07-01 | — | — | EP | disclosed |
| CN-110731961-A | Metal organic framework, pharmaceutical preparation and use thereof in preparing medicament | 芝加哥大学 | 2020-01-31 | — | — | CN | disclosed |
| US-20190209460-A1 | NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | THE UNIVERSITY OF CHICAGO | 2019-07-11 | — | — | US | disclosed |
| US-10206871-B2 | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof | THE UNIVERSITY OF CHICAGO (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180153796-A1 | NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | THE UNIVERSITY OF CHICAGO | 2018-06-07 | — | — | US | disclosed |
| EP-3206987-A1 | NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | The University of Chicago (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20170231903-A1 | NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | THE UNIVERSITY OF CHICAGO (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016061256-A1 | NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | THE UNIVERSITY OF CHICAGO (US) | 2016-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206871-B2 | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof | CD274, PDCD1, PDCD1LG2 | AURKA 924/4885NR1I2 3988/4885CYP1A2 4530/4885 |
| US-20190209460-A1 | NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | CD274, PDCD1, PDCD1LG2 | AURKA 860/4885NR1I2 4016/4885CYP1A2 4492/4885 |
| US-10780045-B2 | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof | CD274, PDCD1, PDCD1LG2 | AURKA 860/4885NR1I2 4016/4885CYP1A2 4492/4885 |
| US-10806694-B2 | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | CD274, PDCD1, PDCD1LG2 | AURKA 788/4885NR1I2 3381/4885CYP1A2 4677/4885 |
| US-20180153796-A1 | NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | CD274, PDCD1, PDCD1LG2 | AURKA 788/4885NR1I2 3381/4885CYP1A2 4677/4885 |
| US-20170231903-A1 | NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | CD274, PDCD1, PDCD1LG2 | AURKA 924/4885NR1I2 3988/4885CYP1A2 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.